Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2008 Oct 21;99(10):1656–1667. doi: 10.1038/sj.bjc.6604712

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2008 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Silencing of Cyr61 eliminated the systemic tumour growth of Du145 cells in vivo. (A, B, C, and D) Either Du145-Luc2/Ctrli #1 or Du145-Luc2/Cyr61i #1 cells (1 × 10⁷) and 5 × 10⁶ of either Du145-Luc2/GFP or Du145-Luc2/Cyr61 cells were injected into each 10 mice tail vein separately. The bioluminescence images were acquired using the IVIS imaging box at indicated time points. Representative mice (8# and 10#) of Du145-Luc2/Ctrli #1, Du145-Luc2/Cyr61i #1 (A) and Du145-Luc2/GFP, Du145-Luc2/Cyr61 (B) were presented for each time point. (C) Average number of metastasis lesions was qualified. (D) The metastasis lesion was picked out to confirm that bioluminescence signalling is not artificial. (E) Immunohistochemistry of Cyr61 in clinical prostate cancer samples and matched normal prostate tissue. Scale bar=100 μm. (F) Elevation of Cyr61 level upon tissue adjacent to tumour and the tumour samples compared with normal prostate tissues free of any pathological alteration; box-and-whisker plots of Cyr61 expression level at different stages of prostate cancer tissues. ^***P<0.001; ^**P<0.01.